2016
Long‐term outcomes in treatment of retroperitoneal sarcomas: A 15 year single‐institution evaluation of prognostic features
Abdelfatah E, Guzzetta AA, Nagarajan N, Wolfgang CL, Pawlik TM, Choti MA, Schulick R, Montgomery EA, Meyer C, Thornton K, Herman J, Terezakis S, Frassica D, Ahuja N. Long‐term outcomes in treatment of retroperitoneal sarcomas: A 15 year single‐institution evaluation of prognostic features. Journal Of Surgical Oncology 2016, 114: 56-64. PMID: 27076350, PMCID: PMC4917421, DOI: 10.1002/jso.24256.Peer-Reviewed Original ResearchConceptsCompartmental resectionRPS patientsSurgical resectionPrognostic factorsR0/R1 marginsR0/R1 resectionEn bloc surgical resectionBloc surgical resectionCornerstone of therapyMainstay of treatmentFive-year survivalRetrospective chart reviewPresence of metastasesEn bloc resectionExtent of resectionConnective tissue tumorsJohns Hopkins HospitalWarrants further investigationR1 resectionRetroperitoneal sarcomaChart reviewMedian survivalR1 marginsDistal recurrenceLocal recurrence
2015
Multimodal Therapy in the Treatment of Prostate Sarcoma: The Johns Hopkins Experience
Ball MW, Sundi D, Reese AC, Meyer CF, Terezakis SA, Efron JE, Schoenberg MP, Epstein JI, Ahuja N, Bivalacqua TJ. Multimodal Therapy in the Treatment of Prostate Sarcoma: The Johns Hopkins Experience. Clinical Genitourinary Cancer 2015, 13: 435-440. PMID: 26003268, DOI: 10.1016/j.clgc.2015.04.011.Peer-Reviewed Original ResearchConceptsCancer-specific survivalRecurrence-free survivalProstate sarcomaOverall survivalSurgical resectionLocal recurrenceMedian recurrence-free survivalFavorable cancer-specific survivalCommon presenting symptomRecords of patientsPatient demographic informationJohns Hopkins ExperienceActuarial OSConcurrent chemotherapyCurative intentMedian OSNeoadjuvant chemoradiationNeoadjuvant radiationOncological outcomesPresenting symptomMost patientsRFS ratesUrinary obstructionMetastatic recurrenceTumor characteristics
2011
Duodenal Adenocarcinoma: Clinicopathologic Analysis and Implications for Treatment
Poultsides GA, Huang LC, Cameron JL, Tuli R, Lan L, Hruban RH, Pawlik TM, Herman JM, Edil BH, Ahuja N, Choti MA, Wolfgang CL, Schulick RD. Duodenal Adenocarcinoma: Clinicopathologic Analysis and Implications for Treatment. Annals Of Surgical Oncology 2011, 19: 1928-1935. PMID: 22167476, PMCID: PMC3663711, DOI: 10.1245/s10434-011-2168-3.Peer-Reviewed Original ResearchConceptsDuodenal adenocarcinomaOverall survivalLymph nodesMultivariate analysisInvolved lymph nodesSmall bowel adenocarcinomaEffective systemic therapyFive-year survivalOnly independent predictorProlongs overall survivalAmpulla of VaterConclusionsThe prognostic significanceAdjuvant chemoradiationBowel adenocarcinomaUnderwent pancreaticoduodenectomySystemic therapyAdequate lymphadenectomyIndependent predictorsLocal recurrenceNodal metastasisClinicopathologic analysisPrognostic significanceClinicopathologic variablesRare cancersAdenocarcinoma
2008
Management of Retroperitoneal Sarcomas
Hueman MT, Herman JM, Ahuja N. Management of Retroperitoneal Sarcomas. Surgical Clinics Of North America 2008, 88: 583-597. PMID: 18514700, DOI: 10.1016/j.suc.2008.03.002.Peer-Reviewed Original ResearchConceptsRetroperitoneal sarcomaLocal recurrenceMorbidity of therapyDistant metastatic diseaseAggressive surgical approachCurative treatment optionManagement of patientsHigh-grade lesionsMetastatic diseaseSurgical therapyTherapeutic challengeSurgical approachTreatment optionsExtent of invasionDisease controlSarcomaCommon typePatientsRecurrenceTherapyMorbidityLesionsManagementDiseaseDiagnosis